Garland Jason K sold $80K of RGEN

Garland Jason K (CFO) sold 530 shares of REPLIGEN CORP (RGEN) at $150.00 on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Garland Jason K
Published Jul 17, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 5:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RGEN
Neutral
high confidence
Mentioned
$RGEN
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RGENNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (530 shares at $150, total $79,500) by the CFO on 2026-07-16, filed on 2026-07-17, under a 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment, but the disclosure lacks any fundamental catalyst (no guidance, deal, or regulatory update).

03

What to watch

Insider sales can be driven by diversification or tax planning; the article provides no context on total holdings, option exercises, or other concurrent insider activity.

Relevance 2/10Novelty 3/10Timing: filed 2026-07-17, transaction dated 2026-07-16

Background

The article is a SEC Form 4 insider transaction disclosure for Repligen Corp (RGEN).

Company-level read

Ticker impact

$RGENNeutralHigh confidence
Context

Repligen CFO Garland Jason K filed a Form 4 open-market sale of 530 shares at $150 on 2026-07-16 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited and short-lived.

Evidence & confidence

The filing is a routine 10b5-1 planned open-market sale with modest size ($79.5k) and no accompanying operational or guidance change in the text.

Market effects

No sector read-through is provided; this appears company-specific and routine.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may not signal reduced confidence and could be ignored by most traders.

Key entities

  • REPLIGEN CORP

    Company whose CFO insider sale is disclosed via SEC Form 4.

  • Garland Jason K

    CFO who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.